{"commentary":{"count":77,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":35,"youtube":29,"podcast":13},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05695508\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"HD10/DSMMXX","nct_id":"NCT05695508","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=hd10-dsmmxx-nct05695508. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"HD10/DSMMXX","arms":[{"description":"Arm A participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.","label":"Arm A Tec-DRd Induction and Tec-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm B participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide, dexamethasone and bortezomib in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.","label":"Arm B Tec-DVRd Induction and Tec-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm C participants will receive maximum 18 cycles of teclistamab SC injection in combination with daratumumab SC and lenalidomide as maintenance therapy.","label":"Arm C Tec-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm A1 participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.","label":"Arm A1 Tec-DRd Induction and Tec-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm C2 participants will receive maximum 18 cycles of talquetamab SC injection in combination with daratumumab SC and lenalidomide as maintenance therapy.","label":"Arm C2 Tal-DR Maintenance","type":"EXPERIMENTAL"},{"description":"Arm D participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by a combination of teclistamab and talquetamab SC injection in maximum 18 cycles of following induction therapy.","label":"Arm D Tec-DRd Induction and Tec-Tal following induction","type":"EXPERIMENTAL"},{"description":"Arm E participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.","label":"Arm E Tal-DRd Induction and Tec-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm E1 participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by talquetamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.","label":"Arm E1 Tal-DRd Induction and Tal-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm F participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, bortezomib, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.","label":"Arm F Tal-DVRd Induction and Tec-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm F1 participants will receive talquetamab as subcutaneous (SC) injection in combination with daratumumab SC, bortezomib, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by talquetamab SC injection in combination with daratumumab SC in maximum 18 cycles of maintenance therapy.","label":"Arm F1 Tal-DVRd Induction and Tal-D Maintenance","type":"EXPERIMENTAL"},{"description":"Arm G participants will receive six 28-day cycles of JNJ-79635322-DRd induction, followed byJNJ-79635322-D treatment for a maximum of eighteen 28-day cycles or until confirmed PD, death, intolerable toxicity, loss to follow-up, or consent withdrawal, whichever comes first. Tec-Tal or JNJ-79635322-D treatment can be discontinued when 12 months of sustained MRD negativity has been observed during the study.","label":"Arm-G JNJ-79635322-DRd induction - JNJ-79635322-D following ind","type":"EXPERIMENTAL"}],"collaborators":["Janssen Research & Development, LLC","Deutsche Studiengruppe Multiples Myelom (DSMM)"],"completion_date":{"date":"2029-09-15","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":160,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Teclistamab (Tec)","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Talquetamab","type":"DRUG"},{"name":"JNJ-79635322","type":"DRUG"}],"last_update":"2025-12-24","lead_sponsor":"University of Heidelberg Medical Center","official_title":"A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-09-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"number of incidence and severity of adverse events [safety and tolerability]","timeFrame":"through study completion, up to 28 months"}],"references":[{"citation":"Raab MS, Weinhold N, Kortum KM, Kronke J, Fenk R, Weisel K, Podola L, Bertsch U, Brobeil A, Mersi J, Huhn S, Arlinghaus R, Hundemer M, Bohl SR, Mai EK, Schub N, Waldschmidt J, Bassermann F, Muller-Tidow C, Heuck C, Sakabedoyan C, Khan J, Ershova E, Koster BD, Engelhardt M, Hanel M, Salwender H, Teipel R, Goldschmidt H, Einsele H, Rasche L; GMMG-HD10/DSMM-XX (MajesTEC-5) investigators. Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Nat Med. 2026 Jul;32(7):2440-2448. doi: 10.1038/s41591-026-04471-x. Epub 2026 Jun 25.","pmid":"42350642","type":"DERIVED"}],"start_date":{"date":"2022-12-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","url":"https://clinicaltrials.gov/study/NCT05695508"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/hd10-dsmmxx-nct05695508"}